{"id":457442,"date":"2021-03-15T08:03:48","date_gmt":"2021-03-15T12:03:48","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=457442"},"modified":"2021-03-15T08:03:48","modified_gmt":"2021-03-15T12:03:48","slug":"mannkind-to-participate-in-2022-medicare-part-d-senior-savings-model-to-make-insulin-more-affordable-for-seniors","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/mannkind-to-participate-in-2022-medicare-part-d-senior-savings-model-to-make-insulin-more-affordable-for-seniors\/","title":{"rendered":"MannKind to Participate in 2022 Medicare Part D Senior Savings Model to Make Insulin More Affordable for Seniors"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">WESTLAKE VILLAGE, Calif., March  15, 2021  (GLOBE NEWSWIRE) &#8212; MannKind Corporation (Nasdaq: MNKD), announced today that it will participate in the 2022 Medicare Part D Senior Savings Model, which is intended to improve the affordability of insulin for Medicare beneficiaries by capping the co-pay per 30-day supply at $35. MannKind will offer all dosage strengths of Afrezza\u00ae (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes.<\/p>\n<p align=\"justify\">According to the Centers for Medicare &amp; Medicaid Services (CMS), a third of Medicare beneficiaries have diabetes, and over 3.3 million beneficiaries use one or more dosage forms of insulin. For many, the cost of insulin can become a barrier to accessing appropriate medical treatment for diabetes management. The Medicare Part D Senior Savings Model, which launched earlier this year, provides seniors greater, and more affordable, access to the treatment options they need.<\/p>\n<p align=\"justify\">&#8220;MannKind is pleased to participate in the 2022 Medicare Part D Senior Savings Model and we are excited to partner with Part D plans to ensure their members have affordable access to the only inhaled insulin therapy,\u201d said Michael Castagna, Chief Executive Officer of MannKind. \u201cThere are gaps in our current healthcare system when it comes to access and affordability, and we believe the Model is an important step toward addressing these issues and a potential improvement in the quality of care for seniors living with diabetes.\u201d<\/p>\n<p align=\"justify\">MannKind\u2019s participation in the Model will commence in 2022 and will join other initiatives that MannKind has introduced in recent years to help patients afford their insulin.\u00a0 Most recently, MannKind launched AfrezzaAssist<sup>SM<\/sup>, which helps facilitate patient access to affordability programs. These programs include a co-pay assistance program for patients with commercial insurance, which lowers copays to as little as $15 (see <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=a_EQkq3ScFKsuON4ecHJgchqmKmjinTTmZSa3W-07ZBNaTa--fMoeIIh6VGx2CGPoTiZXKBWPtmKZmwJG-qYYeKTQoLJnWWGur_xllbAb6raoUVa_GWgix_vyulAHi1p\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/afrezza.com\/savings-program\/<\/a> for more details), as well as a direct purchase cash program that provides a more affordable option for uninsured patients (see <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=a_EQkq3ScFKsuON4ecHJgVNY-H8f2cfXFAIS4icIvnG1548DP1R3HT-u5Rib76uK6WHpgxPfvXTFHjR88v2ogZM49KFxjKTxBXz32dvYZ-4cC2wDQj462xpTU_dYX-wH\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/www.insulinsavings.com\/<\/a> for more details).\u00a0 To learn more about options to help reduce out of pocket costs, patients and healthcare providers can speak with a support specialist at AfrezzaAssist<sup>SM<\/sup> by calling (toll free) 1-844-323-7399 Monday through Friday between 8:00 am and 8:00 pm ET.<\/p>\n<p>\n        <strong>About MannKind Corporation<\/strong>\n      <\/p>\n<p align=\"justify\">MannKind Corporation\u00a0(Nasdaq: MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases.\u00a0MannKind\u00a0is currently commercializing Afrezza\u00ae (insulin human) Inhalation Powder, the Company\u2019s first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in\u00a0the United States, where it is available by prescription from pharmacies nationwide. Afrezza is also available by prescription in\u00a0Brazil\u00a0where it is commercialized by the Company\u2019s partner\u00a0Biomm SA.\u00a0\u00a0MannKind is headquartered in\u00a0Westlake Village, California, and has a state-of-the art manufacturing facility in\u00a0Danbury, Connecticut. The Company also employs field sales and medical representatives across the\u00a0U.S.\u00a0For further information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2wRocN7Id2Zcd02-sjCo1E8VKsjnDo-tX8z1RpOjErR25m8gvwN7lJPWpUh8F4v587JfuzjUcH2_oKDeTOFivD6Zp5JQaPu9TCZzIZQ-9KY=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.mannkindcorp.com<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains forward-looking statements that involve risks and uncertainties, including statements regarding the anticipated terms of the proposed offering and MannKind\u2019s expected use of proceeds from the proposed offering. Words such as \u201cbelieves\u201d, \u201canticipates\u201d, \u201cplans\u201d, \u201cexpects\u201d, \u201cintend\u201d, \u201cwill\u201d, \u201cgoal\u201d, \u201cpotential\u201d and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon MannKind\u2019s current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the utilization of the Medicare Part D Senior Savings Model by beneficiaries, and other risks detailed in MannKind\u2019s filings with the\u00a0Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended\u00a0December\u00a031, 2020\u00a0and subsequent periodic reports on Form 10-Q and current reports on Form 8-K. You\u00a0are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and\u00a0MannKind\u00a0undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.<\/p>\n<p>\n        <strong>Company Contact:<\/strong><br \/>\n        <br \/>818-661-5000<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VEHx93zEneKS0WStrqvY-Z_uGqg-4SHxnh6OXcEcB24pzPvmqS-yT2HwRJEZjg2mVxgE_XhxVd4e59umOfUULhQPrDR1Qdk2bHACXCY2v5s=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">ir@mannkindcorp.com<\/a><\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4OTkwMyM0MDYzNzUyIzIwMDgxMDc=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/e21b9786-cc1f-4155-9ff2-5befcbd3452c\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WESTLAKE VILLAGE, Calif., March 15, 2021 (GLOBE NEWSWIRE) &#8212; MannKind Corporation (Nasdaq: MNKD), announced today that it will participate in the 2022 Medicare Part D Senior Savings Model, which is intended to improve the affordability of insulin for Medicare beneficiaries by capping the co-pay per 30-day supply at $35. MannKind will offer all dosage strengths of Afrezza\u00ae (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes. According to the Centers for Medicare &amp; Medicaid Services (CMS), a third of Medicare beneficiaries have diabetes, and over 3.3 million beneficiaries use one or more dosage forms of insulin. For many, the cost of insulin can become a barrier to accessing appropriate medical treatment &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/mannkind-to-participate-in-2022-medicare-part-d-senior-savings-model-to-make-insulin-more-affordable-for-seniors\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;MannKind to Participate in 2022 Medicare Part D Senior Savings Model to Make Insulin More Affordable for Seniors&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-457442","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>MannKind to Participate in 2022 Medicare Part D Senior Savings Model to Make Insulin More Affordable for Seniors - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/mannkind-to-participate-in-2022-medicare-part-d-senior-savings-model-to-make-insulin-more-affordable-for-seniors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MannKind to Participate in 2022 Medicare Part D Senior Savings Model to Make Insulin More Affordable for Seniors - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WESTLAKE VILLAGE, Calif., March 15, 2021 (GLOBE NEWSWIRE) &#8212; MannKind Corporation (Nasdaq: MNKD), announced today that it will participate in the 2022 Medicare Part D Senior Savings Model, which is intended to improve the affordability of insulin for Medicare beneficiaries by capping the co-pay per 30-day supply at $35. MannKind will offer all dosage strengths of Afrezza\u00ae (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes. According to the Centers for Medicare &amp; Medicaid Services (CMS), a third of Medicare beneficiaries have diabetes, and over 3.3 million beneficiaries use one or more dosage forms of insulin. For many, the cost of insulin can become a barrier to accessing appropriate medical treatment &hellip; Continue reading &quot;MannKind to Participate in 2022 Medicare Part D Senior Savings Model to Make Insulin More Affordable for Seniors&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/mannkind-to-participate-in-2022-medicare-part-d-senior-savings-model-to-make-insulin-more-affordable-for-seniors\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-15T12:03:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4OTkwMyM0MDYzNzUyIzIwMDgxMDc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mannkind-to-participate-in-2022-medicare-part-d-senior-savings-model-to-make-insulin-more-affordable-for-seniors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mannkind-to-participate-in-2022-medicare-part-d-senior-savings-model-to-make-insulin-more-affordable-for-seniors\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"MannKind to Participate in 2022 Medicare Part D Senior Savings Model to Make Insulin More Affordable for Seniors\",\"datePublished\":\"2021-03-15T12:03:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mannkind-to-participate-in-2022-medicare-part-d-senior-savings-model-to-make-insulin-more-affordable-for-seniors\\\/\"},\"wordCount\":704,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mannkind-to-participate-in-2022-medicare-part-d-senior-savings-model-to-make-insulin-more-affordable-for-seniors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4OTkwMyM0MDYzNzUyIzIwMDgxMDc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mannkind-to-participate-in-2022-medicare-part-d-senior-savings-model-to-make-insulin-more-affordable-for-seniors\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mannkind-to-participate-in-2022-medicare-part-d-senior-savings-model-to-make-insulin-more-affordable-for-seniors\\\/\",\"name\":\"MannKind to Participate in 2022 Medicare Part D Senior Savings Model to Make Insulin More Affordable for Seniors - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mannkind-to-participate-in-2022-medicare-part-d-senior-savings-model-to-make-insulin-more-affordable-for-seniors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mannkind-to-participate-in-2022-medicare-part-d-senior-savings-model-to-make-insulin-more-affordable-for-seniors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4OTkwMyM0MDYzNzUyIzIwMDgxMDc=\",\"datePublished\":\"2021-03-15T12:03:48+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mannkind-to-participate-in-2022-medicare-part-d-senior-savings-model-to-make-insulin-more-affordable-for-seniors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mannkind-to-participate-in-2022-medicare-part-d-senior-savings-model-to-make-insulin-more-affordable-for-seniors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mannkind-to-participate-in-2022-medicare-part-d-senior-savings-model-to-make-insulin-more-affordable-for-seniors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4OTkwMyM0MDYzNzUyIzIwMDgxMDc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4OTkwMyM0MDYzNzUyIzIwMDgxMDc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mannkind-to-participate-in-2022-medicare-part-d-senior-savings-model-to-make-insulin-more-affordable-for-seniors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MannKind to Participate in 2022 Medicare Part D Senior Savings Model to Make Insulin More Affordable for Seniors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MannKind to Participate in 2022 Medicare Part D Senior Savings Model to Make Insulin More Affordable for Seniors - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/mannkind-to-participate-in-2022-medicare-part-d-senior-savings-model-to-make-insulin-more-affordable-for-seniors\/","og_locale":"en_US","og_type":"article","og_title":"MannKind to Participate in 2022 Medicare Part D Senior Savings Model to Make Insulin More Affordable for Seniors - Market Newsdesk","og_description":"WESTLAKE VILLAGE, Calif., March 15, 2021 (GLOBE NEWSWIRE) &#8212; MannKind Corporation (Nasdaq: MNKD), announced today that it will participate in the 2022 Medicare Part D Senior Savings Model, which is intended to improve the affordability of insulin for Medicare beneficiaries by capping the co-pay per 30-day supply at $35. MannKind will offer all dosage strengths of Afrezza\u00ae (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes. According to the Centers for Medicare &amp; Medicaid Services (CMS), a third of Medicare beneficiaries have diabetes, and over 3.3 million beneficiaries use one or more dosage forms of insulin. For many, the cost of insulin can become a barrier to accessing appropriate medical treatment &hellip; Continue reading \"MannKind to Participate in 2022 Medicare Part D Senior Savings Model to Make Insulin More Affordable for Seniors\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/mannkind-to-participate-in-2022-medicare-part-d-senior-savings-model-to-make-insulin-more-affordable-for-seniors\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-15T12:03:48+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4OTkwMyM0MDYzNzUyIzIwMDgxMDc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mannkind-to-participate-in-2022-medicare-part-d-senior-savings-model-to-make-insulin-more-affordable-for-seniors\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mannkind-to-participate-in-2022-medicare-part-d-senior-savings-model-to-make-insulin-more-affordable-for-seniors\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"MannKind to Participate in 2022 Medicare Part D Senior Savings Model to Make Insulin More Affordable for Seniors","datePublished":"2021-03-15T12:03:48+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mannkind-to-participate-in-2022-medicare-part-d-senior-savings-model-to-make-insulin-more-affordable-for-seniors\/"},"wordCount":704,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mannkind-to-participate-in-2022-medicare-part-d-senior-savings-model-to-make-insulin-more-affordable-for-seniors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4OTkwMyM0MDYzNzUyIzIwMDgxMDc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mannkind-to-participate-in-2022-medicare-part-d-senior-savings-model-to-make-insulin-more-affordable-for-seniors\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/mannkind-to-participate-in-2022-medicare-part-d-senior-savings-model-to-make-insulin-more-affordable-for-seniors\/","name":"MannKind to Participate in 2022 Medicare Part D Senior Savings Model to Make Insulin More Affordable for Seniors - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mannkind-to-participate-in-2022-medicare-part-d-senior-savings-model-to-make-insulin-more-affordable-for-seniors\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mannkind-to-participate-in-2022-medicare-part-d-senior-savings-model-to-make-insulin-more-affordable-for-seniors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4OTkwMyM0MDYzNzUyIzIwMDgxMDc=","datePublished":"2021-03-15T12:03:48+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mannkind-to-participate-in-2022-medicare-part-d-senior-savings-model-to-make-insulin-more-affordable-for-seniors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/mannkind-to-participate-in-2022-medicare-part-d-senior-savings-model-to-make-insulin-more-affordable-for-seniors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mannkind-to-participate-in-2022-medicare-part-d-senior-savings-model-to-make-insulin-more-affordable-for-seniors\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4OTkwMyM0MDYzNzUyIzIwMDgxMDc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4OTkwMyM0MDYzNzUyIzIwMDgxMDc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mannkind-to-participate-in-2022-medicare-part-d-senior-savings-model-to-make-insulin-more-affordable-for-seniors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"MannKind to Participate in 2022 Medicare Part D Senior Savings Model to Make Insulin More Affordable for Seniors"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/457442","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=457442"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/457442\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=457442"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=457442"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=457442"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}